A transcript of this podcast and more information about Tom Wadden is available on the website of the Duke World Food Policy Center at https://wfpc.sanford.duke.edu/podcast... Much attention has been paid recently in both scientific circles and in the media to a drug for weight loss newly...
https://www.empr.com/home/news/drugs-in-the-pipeline/oral-prodrug-of-testosterone-fast-tracked-for-nonalcoholic-steatohepatitis/ The Food and Drug Administration (FDA) has granted Fast Track designation to LPCN 1144 for the treatment of noncirrhotic nonalcoholic steatohepatitis (NASH). LPCN...
https://www.sec.gov/Archives/edgar/data/1535955/000149315221026815/ex99-4.htm LPCN 1144 IMPROVES BODY COMPOSITION IN BIOPSY-CONFIRMED NASH PATIENTS Background: Non-alcoholic Steatohepatitis (NASH) is a common cause of liver disease and rapidly rising to be the leading indication for liver...
https://www.prnewswire.com/news-releases/lipocine-announces-positive-lpcn-1144-nash-open-label-extension-study-results-301545697.html LPCN 1144 was well tolerated over 72-week exposure with no observed safety signals Liver injury markers were reduced and maintained with extended LPCN 1144...
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.